Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin-Based Induction Chemo vs Chemoradiotherapy in Esophageal Cancer
NCT00525915Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2005
- Primary completion
- Mar 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in esophageal carcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Pathologic Complete Response Rate and Percentage of patients with <50% residual cancer. Started Apr 2005; status: completed.
02
Drugs
oxaliplatin
03
Conditions
esophageal carcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00525915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525915.